FDA Panel Votes ‘No’ to Approving Aducanumab for Alzheimer’s, Citing Inconsistent Data,

Also, clinical trials moving forward would have to test the drug against the standard of care, which in this case would be aducanumab. If approved, the …, Also, clinical trials moving forward would have to test the drug against the standard of care, which in this case would be aducanumab. If approved, the …, Read More